Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Author:

Roschewski Mark1ORCID,Lionakis Michail S.2,Sharman Jeff P.3,Roswarski Joseph4,Goy Andre5,Monticelli M. Andrew6,Roshon Michael78ORCID,Wrzesinski Stephen H.9ORCID,Desai Jigar V.2ORCID,Zarakas Marissa A.2,Collen Jacob10,Rose Keith M.5,Hamdy Ahmed11,Izumi Raquel11,Wright George W.12ORCID,Chung Kevin K.9ORCID,Baselga Jose13ORCID,Staudt Louis M.1ORCID,Wilson Wyndham H.1

Affiliation:

1. Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.

2. Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.

3. Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR, USA.

4. Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, MD, USA.

5. John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ, USA.

6. Rocky Mountain Cancer Center, US Oncology, Colorado Springs, CO, USA.

7. Department of Emergency Medicine, Penrose-St. Francis Health Services, Colorado Springs, CO, USA.

8. US Acute Care Solutions, Canton, OH, USA.

9. Department of Medicine, St. Peter’s Hospital and US Oncology, Albany, NY, USA.

10. Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

11. Acerta Pharma, South San Francisco, CA, USA.

12. Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD, USA.

13. AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA.

Abstract

Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19.

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Division of Intramural Research, National Cancer Institute

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference54 articles.

Cited by 301 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3